Azithromycin

C. diff Risk

Low

Oral Bioavailability

Moderate

Approximate Cost

Dosing

Community acquired pneumonia
500 mg PO/IV on Day 1 then 250 mg daily for 4 days

  • Treatment duration may vary depending upon clinical syndrome

MAC prophylaxis for certain patients with HIV if indicated
1250 mg PO weekly

General Information

Common Usage

  • Community acquired pneumonia

  • Upper respiratory tract bacterial infections

  • Mycobacterium avium complex (MAC) prophylaxis in certain patients with HIV

Drug Monitoring

Monitor QTc in patients with increased risk of prolongation

Adverse Effects

Prolongation of QTc interval. Association with increased cardiovascular mortality in observational studies.

May exacerbate muscle weakness in persons with myasthenia gravis. Use with caution.

Major Interactions

  • Other drugs that prolong QTc interval

  • Increases cyclosporine levels

  • May increase digoxin levels

  • Concomitant use of statins may increase risk of rhabdomyolysis

Additional Information

May exacerbate muscle weakness in persons with myasthenia gravis. Use with caution.

Pharmacology

Antimicrobial class: Macrolide

Pregnancy category: B

Average serum half life: 68 hours

Biliary penetration: Therapeutic

CSF penetration: Poor

Lung penetration: Therapeutic

Urine penetration: Poor